Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565901 · ClinicalTrials.gov registry record · Phase 1
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02565901 is a Phase 1 study that was terminated before completion, run by University of Washington. The registered enrollment target is 28 participants.
The verdict
NCT02565901, a Phase 1 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This partially randomized phase I/II trial studies the side effects and how well sirolimus works when given together with docetaxel and carboplatin in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). Biological therapies, such as sirolimus, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sirolimus together with docetaxel and carboplatin may kill more tumor cells.
Interventions
- DRUG Sirolimus
- DRUG Carboplatin
- DRUG Docetaxel
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2020-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02565901
The ClinicalTrials.gov registry entry for NCT02565901 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sirolimus is the first listed.
NCT02565901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02565901 about?
NCT02565901 is a clinical study titled "Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer". This partially randomized phase I/II trial studies the side effects and how well sirolimus works when given together with docetaxel and carboplatin in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). Biological therapies, such as s...
What is the current status of trial NCT02565901?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-02-29. Estimated completion is 2020-06-16.
What interventions are being tested in trial NCT02565901?
The interventions under investigation include: Sirolimus (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02565901?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.